September 2024

In Phase Ia clinical study, GZR4 demonstrated favorable safety and tolerability profiles in healthy subjects, maintaining a stable glucose-lowering effect for up to one week with a single administration.In Phase Ib clinical study, patients with Type 2 diabetes mellitus (T2DM) receiving six weeks of

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: